Choroidal neovascularization suppressor or drusen formation suppressor, and method for assessing or screening for same

A method of preventing and/or treating age-related macular degeneration in a patient, said method comprising administering a propionic acid-based nonsteroidal anti-inflammatory drug, an aminoaryl carboxylic acid-based nonsteroidal anti-inflammatory drug, an aldose reductase inhibitor, a leukotriene receptor antagonist, a chemical mediator release suppressor, or a thromboxane A2 receptor antagonist as an active ingredient, wherein the active ingredient is formulated as an oral agent, an ophthalmic solution, an ophthalmic ointment, or an injection provided it is not an ophthalmic injection, wherein the aldose reductase inhibitor is epalrestat and/or a pharmaceutically acceptable salt thereof to the patient,

• wherein said propionic acid-based nonsteroidal anti-inflammatory drug is at least one selected from the group consisting of zaltoprofen, oxaprozin, tiaprofenic acid, and pharmaceutically acceptable salts thereof
• wherein said aminoaryl carboxylic acid-based nonsteroidal anti-inflammatory drug is at least one selected from the group consisting of flufenamic acid, mefenamic acid, and pharmaceutically acceptable salts thereof,
• wherein said leukotriene receptor antagonist is at least one selected from the group consisting of zafirlukast, montelukast, pranlukast, and pharmaceutically acceptable salts thereof,
• wherein said chemical mediator release suppressor is amlexanox and/or a pharmaceutically acceptable salt thereof, and/or
• wherein said thromboxane A2 receptor antagonist is seratrodast and/or a pharmaceutically acceptable salt thereof.